Department of Clinical Pharmacy and Pharmacy Practice, Jos University Teaching Hospital/University of Jos, Jos, Nigeria.
Department of Clinical Pharmacy & Biopharmacy, Faculty of Pharmacy, University of Lagos, Idiaraba Campus, Lagos, Nigeria.
Afr Health Sci. 2021 Sep;21(3):1027-1039. doi: 10.4314/ahs.v21i3.10.
Despite close to two decades of antiretroviral therapy (ART) in Nigeria, data on late on-onset ART-associated adverse drug reactions (ADRs) are sparse.
To describe early and late-onset ADRs and compare their incidence in an outpatient HIV positive Cohort on ART.
We described the incidence of clinical ADRs identified and documented in an outpatient clinic cohort of HIV-positive patients treated between June 2004 and December 2015 at a tertiary health facility in Nigeria. Incidence rates of ADRs during the first and subsequent years of ART were compared.
of the 13,983 patients' data analyzed, 9317 were females (66%), and those in the age bracket of 25 to 45 years made up 78% of the studied population. During 52,411 person-years (py) of ART, 1485 incident ADRs were recorded; Incidence rate (IR) 28.3 (95% confidence interval [CI] 26.9:29.8) ADRs per 1000 person-years (py) of ART. The IR of ADRs was about two times higher in the first year of ART compared to subsequent years of treatment; crude incidence rate ratio (IRR) 1.77 (95% CI 1.59:1.97). Anemia, hypersensitivity reactions, and nervous system disorders had 7, 23, and 5 times higher incidence, respectively, in the first year of therapy, compared to subsequent years.
The first year of ART is the period of highest risk of ADRs. Individual and programmatic treatment success in resource-limited settings requires strategies for early identification and management of ADR during the period of greatest risk of ADRs.
尽管在尼日利亚已经有近二十年的抗逆转录病毒疗法(ART),但是关于晚期开始的 ART 相关药物不良反应(ADR)的数据却很少。
描述门诊 HIV 阳性接受 ART 治疗的队列中早期和晚期发生的 ADR,并比较它们的发生率。
我们描述了 2004 年 6 月至 2015 年 12 月在尼日利亚一家三级医疗机构的门诊 HIV 阳性患者队列中发现并记录的临床 ADR 的发生率。比较了在 ART 的前几年和随后几年中 ADR 的发生率。
在分析的 13983 名患者数据中,9317 名女性(66%),年龄在 25 至 45 岁的患者占研究人群的 78%。在 52411 人年(py)的 ART 期间,共记录到 1485 例新发生的 ADR;ART 每 1000 人年(py)的发生率(IR)为 28.3(95%置信区间 [CI] 26.9:29.8)。ART 治疗的第一年与随后几年相比,ADR 的发生率大约高出两倍;粗发病率比(IRR)为 1.77(95% CI 1.59:1.97)。第一年的治疗中,贫血、过敏反应和神经系统疾病的发生率分别高出 7、23 和 5 倍。
ART 的第一年是 ADR 风险最高的时期。在资源有限的环境中,需要针对个体和项目的治疗成功制定策略,以在 ADR 风险最高的时期尽早识别和管理 ADR。